Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma

Cancer

Volumn 118, Issue 9, 2012, Pages 2494-2506

  Ichikawa, Jiro ^a,b   Cole, Heather A ^a   Magnussen, Robert A ^a   Mignemi, Nicholas A ^a   Butler, Matthew ^a   Holt, Ginger E ^a   O'Rear, Lynda ^a   Yuasa, Masato ^a   Pabla, Baldeep ^a   Haro, Hirotaka ^b   Cates, Justin M M ^a   Hamm, Heidi E ^a   Schwartz, Herbert S ^a   Schoenecker, Jonathan G ^a,c  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

coagulation; low molecular weight heparin; osteosarcoma; thrombin; tissue factor

Indexed keywords

ENOXAPARIN; FIBRIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HEMIPELVECTOMY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBECTOMY; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANIMALS; BLOOD COAGULATION; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEPARIN; HUMANS; MALE; MICE; MIDDLE AGED; OSTEOSARCOMA; THROMBIN; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84860220047     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26518     Document Type: Article

References (36)

1. Anderson AR, Weaver AM, Cummings PT, Quaranta V,. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006; 127: 905-915.
2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR,. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715-722.
3. Nierodzik ML, Karpatkin S,. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10: 355-362.
4. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A,. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995; 92: 8205-8209.
5. Sud R, Khorana AA,. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009; 123 (suppl 4): S18-S21.
6. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998; 152: 399-411.
7. Lykke J, Nielsen HJ,. The role of tissue factor in colorectal cancer. Eur J Surg Oncol. 2003; 29: 417-422.
8. Casara D, Cartel G, Costa S, Pengo V, Fiorentino M, Calzavara F,. Radioiodinated fibrinogen in the evaluation of patients with osteosarcoma. Eur J Cancer. 1980; 16: 261-265.
9. Schmidt J, Strauss GP, Schon A, et al. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation. 1988; 39: 151-160.
10. Emeis JJ, Edgell CJ,. Fibrinolytic properties of a human endothelial hybrid cell line (Ea.hy 926). Blood. 1988; 71: 1669-1675.
11. Bauer J, Margolis M, Schreiner C, et al. In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J Cell Physiol. 1992; 153: 437-449.
12. Campbell JE, Brummel-Ziedins KE, Butenas S, Mann KG,. Cellular regulation of blood coagulation: a model for venous stasis. Blood. 2010; 116: 6082-6091.
13. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977; 12: 11-15.
14. Fogh J, Fogh JM, Orfeo T,. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59: 221-226.
15. Cailleau R, Young R, Olive M, Reeves WJ Jr,. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974; 53: 661-674.
16. Soule HD, Vazguez J, Long A, Albert S, Brennan M,. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51: 1409-1416.
17. Mielicki WP, Gordon SG,. Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coagul Fibrinolysis. 1993; 4: 441-446.
18. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998; 91: 4216-4223.
19. Chandler WL, Roshal M,. Optimization of plasma fluorogenic thrombin-generation assays. Am J Clin Pathol. 2009; 132: 169-179.
20. Hemker HC, Willems GM, Beguin S,. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost. 1986; 56: 9-17.
21. Gordon N, Kleinerman ES,. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010; 23: 189-196.
22. Cole HA, Ichikawa J, Colvin DC, O'Rear L, Schoenecker JG,. Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis. J Orthop Res. [published online ahead of print June 8, 2011.]
23. Grimm J, Potthast A, Wunder A, Moore A,. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer. 2003; 106: 806-811.
24. Dupont WD, Plummer WD Jr,. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998; 19: 589-601.
25. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005; 22: 319-329.
26. Shao ZM, Wu J, Shen ZZ, Barsky SH,. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res. 1998; 18: 1435-1439.
27. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP,. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat. 1994; 31: 325-335.
28. Wang LL,. Biology of osteogenic sarcoma. Cancer J. 2005; 11: 294-305.
29. Horowitz NA, Blevins EA, Miller WM, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011.
30. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL,. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002; 62: 6966-6972.
31. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A,. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006; 96: 816-821.
32. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2: 1266-1271.
33. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23: 2130-2135.
34. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L,. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000; 18: 261-271.
35. Pautke C, Schieker M, Tischer T, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 2004; 24: 3743-3748.
36. Clover J, Gowen M,. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone. 1994; 15: 585-591.